|Ticker||Status||Jurisdiction||Filing Date||CP Start||CP End||CP Loss||Deadline|
|Ticker||Case Name||Status||CP Start||CP End||Deadline||Settlement Amt|
|Ticker||Name||Date||Analyst Firm||Up/Down||Target ($)||Rating Change||Rating Current|
MAPS Public Benefit Corporation (MAPS PBC), the nonprofit’s clinical-stage private arm, published new data from its second multi-site, ethno-racially diverse Phase 3 clinical study of MDMA-assisted therapy for PTSD in Nature Medicine.
The randomized MAPP2 study gave participants a split dose, separated by 1.5 to 2 hours, of 80 or 120 mg of MDMA hydrochloride (or placebo,) and following a 40 to 60 mg dose during three therapy sessions. The placebo group received extended therapy sessions. Continue reading HERE.
Recent peer-reviewed research published in the journal Nature posits that a small dose of MDMA could be helpful against uncomfortable or difficult experiences and amplify positive ones when combined with either psilocybin or LSD.
The study, published in August and authored by researchers from Imperial College London (ICL) and New York University’s Langone Center for Psychedelic Medicine delves into a hypothesis of “candy-flipping,” clinical research conducted by MindMed’s (NASDAQ:MNMD) research collaborator Dr. Matthias Liechti and his team at University Hospital Basel. Read more HERE.
On September 12, the House Rules Committee voted on one of a series of large-scale budget bills which include recently introduced bipartisan marijuana and psychedelics amendments.
The committee’s decision is key, as it is the immediate prior step for proposals to make it, or not, to the House floor. The vote was around the Department of Defense (DoD) FY2024 appropriations bill HR 4365. Read more HERE.
Scottish Advocate, the country's top attorney, replied to a request from the Parliament’s cross-committee on tackling drug deaths and drug harm for an update on her consideration of a prosecution policy for a pilot safer drug consumption facility in Glasgow.
In her statement, Dorothy Bain KC (Independent party) said she "would be prepared to publish” a prosecution policy by which “it would not be in the public interest to prosecute drug users for simple possession offenses” committed within the center, located in an area “where public injecting is already a significant issue.” Continue reading HERE.
A Swedish foundation is supporting mental health innovation with a new €3M psychedelic science initiative.
Michigan lawmakers passed a bicameral resolution urging Congress to prioritize research on psychedelics and other alternative therapies for veterans.
'Wolf Of Wall Street' Jordan Belfort embraces ibogaine for addiction recovery with the help of “The psychedelic concierge.”
The psychedelic drugs market will generate over $12 billion in the next 12 years, a NY consulting firm predicted.
How can America unlock $28 billion in new taxes? Benefits await from psychedelics legalization.
Plant medicine takes center stage in pharma's shadow: Cannabis and the rise of natural remedies.
See Also: Last Week's Edition Of 'Psyched'
AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, Sept. 11 at $1.75 and almost immediately price fell $0.03. Prior week’s opening (Tuesday 5) had been slightly higher, at $1.79, a recovery from prior week’s at $1.65.
Week’s closing price on Friday 15 was $1.74, closer to prior Friday 8’s close at $1.78 yet lower than Friday 1’s at $1.83.
Week’s highest was $1.77, achieved multiple times throughout the week. Still, a bit lower than prior weeks’ highest points at $1.8 and $1.85, respectively.
Week’s lowest was $1.71 during Thursday 14, slightly down from prior week’s lowest $1.73, yet higher than two weeks’ past lowest at $1.63.
The ETF’s yearly price range has again been changed, now set between $3.24 and $1.62. A considerable drop from just last week’s $3.64 highest and keeping the low at $1.62.
GH Research (NASDAQ:GHRS) closed on Friday at solid $10.50, up from prior Friday 8 closing at $10.00 and also Friday 1’s at $10.40.
COMPASS Pathways (NASDAQ:CMPS) closed at $9.41, same as last two Fridays.
Mind Medicine (MindMed) (NASDAQ:MNMD) closed at $4.17, a high from Friday 8’s closing at $4.00 and also Friday 1 at $4.09.
Enveric Biosciences (NASDAQ:ENVB) closed at $2.28, up from Friday 8’s closing at $2.22 and Friday 1’s $2.12.
Silo Pharma (NASDAQ:SILO) closed at $1.85, down from Friday 8’s closing at $1.98 and Friday 1’s at $2.02.
Bright Minds Biosciences (NASDAQ:DRUG) closed at $1.57, down from Friday 8’s closing at $1.92 and certainly lower than Friday 1’s at $2.19.
FSD Pharma (NASDAQ:HUGE) closed at $1.5, jumping from Friday 8’s closing at $1.23 and Friday 1’s at $1.28.
atai Life Sciences (NASDAQ:ATAI) closed at $1.45, slightly up from Friday 8’s closing at $1.43 yet down from solid $1.53 on Friday 1.
Incannex Healthcare (NASDAQ:IXHL) closed at $1.40, up from Friday 8’s closing at $1.33, and slightly below closing price $1.45 on Friday 1.
Seelos Therapeutics (NASDAQ:SEEL) closed at $0.92, following Friday 8’s at $1.01 and Friday 1’s at $1.09.
Best numbers of the week were for FSD, and the worst ones for Bright Minds.
The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this September 27-28 for its 17th edition. Get your tickets TODAY and come join us at the epicenter of cannabis investment and branding!